secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001493152-24-014355
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment
--------------------------------------------------------------------------------

- 10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.
- GraftAssure RUO launch expected Q2 2024 at select US/EU transplant centers, broader rollout H2 2024.
- Bio-Rad gets exclusive global distribution rights outside US/Germany; option for IVD rights upon FDA clearance with second equity investment.
- Transplant monitoring market estimated over $1B with 157K annual transplants and 9.1% growth.
- Bio-Rad makes initial equity investment in Oncocyte; specific amount not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer